7548. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
作者: Peter Richardson.;Ivan Griffin.;Catherine Tucker.;Dan Smith.;Olly Oechsle.;Anne Phelan.;Michael Rawling.;Edward Savory.;Justin Stebbing.
来源: Lancet. 2020年395卷10223期e30-e31页 7551. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.
Since Dec 31, 2019, the Chinese city of Wuhan has reported an outbreak of atypical pneumonia caused by the 2019 novel coronavirus (2019-nCoV). Cases have been exported to other Chinese cities, as well as internationally, threatening to trigger a global outbreak. Here, we provide an estimate of the size of the epidemic in Wuhan on the basis of the number of cases exported from Wuhan to cities outside mainland China and forecast the extent of the domestic and global public health risks of epidemics, accounting for social and non-pharmaceutical prevention interventions.
7556. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
Asthma is a disease of reversible airflow obstruction characterised clinically by wheezing, shortness of breath, and coughing. Increases in airway type 2 cytokine activity, including interleukin-4 (IL-4), IL-5, and IL-13, are now established biological mechanisms in asthma. Inhaled corticosteroids have been the foundation for asthma treatment, in a large part because they decrease airway type 2 inflammation. However, inhaled or systemic corticosteroids are ineffective treatments in many patients with asthma and few treatment options exist for patients with steroid resistant asthma. Although mechanisms for corticosteroid refractory asthma are likely to be numerous, the development of a new class of biologic agents that target airway type 2 inflammation has provided a new model for treating some patients with corticosteroid refractory asthma. The objective of this Therapeutic paper is to summarise the new type 2 therapeutics, with an emphasis on the biological rationale and clinical efficacy of this new class of asthma therapeutics.
7558. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.
作者: Ole-Johan Skrede.;Sepp De Raedt.;Andreas Kleppe.;Tarjei S Hveem.;Knut Liestøl.;John Maddison.;Hanne A Askautrud.;Manohar Pradhan.;John Arne Nesheim.;Fritz Albregtsen.;Inger Nina Farstad.;Enric Domingo.;David N Church.;Arild Nesbakken.;Neil A Shepherd.;Ian Tomlinson.;Rachel Kerr.;Marco Novelli.;David J Kerr.;Håvard E Danielsen.
来源: Lancet. 2020年395卷10221期350-360页
Improved markers of prognosis are needed to stratify patients with early-stage colorectal cancer to refine selection of adjuvant therapy. The aim of the present study was to develop a biomarker of patient outcome after primary colorectal cancer resection by directly analysing scanned conventional haematoxylin and eosin stained sections using deep learning.
7559. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial.
作者: Ian G Stiell.;Marco L A Sivilotti.;Monica Taljaard.;David Birnie.;Alain Vadeboncoeur.;Corinne M Hohl.;Andrew D McRae.;Brian H Rowe.;Robert J Brison.;Venkatesh Thiruganasambandamoorthy.;Laurent Macle.;Bjug Borgundvaag.;Judy Morris.;Eric Mercier.;Catherine M Clement.;Jennifer Brinkhurst.;Connor Sheehan.;Erica Brown.;Marie-Joe Nemnom.;George A Wells.;Jeffrey J Perry.
来源: Lancet. 2020年395卷10221期339-349页
Acute atrial fibrillation is the most common arrythmia treated in the emergency department. Our primary aim was to compare conversion to sinus rhythm between pharmacological cardioversion followed by electrical cardioversion (drug-shock), and electrical cardioversion alone (shock-only). Our secondary aim was to compare the effectiveness of two pad positions for electrical cardioversion.
|